TY - JOUR
KW - Buprenorphine -- Legislation and Jurisprudence
KW - Workforce
KW - prescriptive authority
KW - Substance Use Disorders -- Drug Therapy
KW - Analgesics, Opioid -- Legislation and Jurisprudence
AU - Brendan Saloner
AU - Barbara Andraka Christou
AU - Adam J. Gordon
AU - Bradley D. Stein
A1 - 
AD - Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Health Management and Informatics, University of Central Florida, Orlando, FL, USA; Department of Internal Medicine, University of Central Florida, Orlando, FL, USA; Vulnerable Veteran Innovative PACT (VIP) Initiative, VA Salt Lake City Health Care System, Salt Lake City, UT, USA; Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, UT, USA; Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA), Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; RAND Corporation, Pittsburgh, PA, USA
BT - Substance Abuse
C5 - Education & Workforce; Healthcare Policy; Opioids & Substance Use
CP - 2
CY - Philadelphia, Pennsylvania
DO - 10.1080/08897077.2021.1903659
IS - 2
JF - Substance Abuse
LA - English
M1 - Journal Article
PB - Taylor & Francis Ltd
PP - Philadelphia, Pennsylvania
PY - 2021
SN - 0889-7077
SP - 153
EP - 157
EP - 
T1 - It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver
T2 - Substance Abuse
TI - It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver
U1 - Education & Workforce; Healthcare Policy; Opioids & Substance Use
U3 - 10.1080/08897077.2021.1903659
UR - https://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=150408624&site=ehost-live
VL - 42
VO - 0889-7077
Y1 - 2021
Y2 - 04
ER -